Guillain‐Barré Syndrome in an Australian State Using Both mRNA and Adenovirus‐Vector SARS‐CoV‐2 Vaccines.

Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. We read the two recent reports of Guillain-Barré syndrome (GBS) following SARS-CoV-2 vaccination with interest and were inspired to review GBS reports submitted to our enhanced spontaneous surveillance system in Victoria, Australia (SAEFVIC, Surveillance of Adverse Events Following Vaccination in the Community).1-3 Since 21 February 2021, Australia has administered both the AstraZeneca-Oxford (ChAdOx1-S) and Pfizer-BioNTech (BNT162b2) vaccines according to a risk-stratified rollout schedule, initially targeting higher risk groups including healthcare and border workers, as well as residents in aged care facilities (RACF). Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines. [Extracted from the article]